中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2008年
12期
840-843
,共4页
许东奎%张雪梅%赵平%蔡建春%赵丹%谭文%郭永丽%林东昕
許東奎%張雪梅%趙平%蔡建春%趙丹%譚文%郭永麗%林東昕
허동규%장설매%조평%채건춘%조단%담문%곽영려%림동흔
癌,肝细胞%环氧化酶-2%单核苷酸多态
癌,肝細胞%環氧化酶-2%單覈苷痠多態
암,간세포%배양화매-2%단핵감산다태
Carcinoma,hepatocellular%Cyclooxygenase-2%Single Nucleotide Polymorphism
目的 探讨COX-2基因启动子区的单核苷酸多态与肝癌发生风险的关系.方法 研究对象包括270例肝癌病人和540例正常对照.采用PCR-限制性片段长度多态方法 进行COX-2基因启动子区-1290A>G,-1195G>A和-765G>C多态的基因型分析,不同基因型与单体型携带者发生肝癌的相对风险度的评估使用比值比(OR)及95%可信区间(CI).结果 多变量logistic回归分析显示-1195AA和-765GC基因型与肝癌风险增高相关,OR值分别为1.57(95%CI=1.01~2.44)和2.89(95%CI=1.65~5.08).单体型分析显示:与A_1290-G-1195-G_765相比较,含有-1195A等位基因的A-1290-A-1195-G-765和A-1290-A-1195-C-765两种单体型发生肝癌的相对风险增高,OR值分别为1.27(95%CI=1.01~1.60)和7.95(95%CI=1.76~36.02).同时包含-1195A等位基因和-765C等位基因的单体型发生肝癌的OR值较高.结论 COX-2基因启动子区的-1195G>A和-765G>C单核苷酸多态与肝癌遗传易感性相关.
目的 探討COX-2基因啟動子區的單覈苷痠多態與肝癌髮生風險的關繫.方法 研究對象包括270例肝癌病人和540例正常對照.採用PCR-限製性片段長度多態方法 進行COX-2基因啟動子區-1290A>G,-1195G>A和-765G>C多態的基因型分析,不同基因型與單體型攜帶者髮生肝癌的相對風險度的評估使用比值比(OR)及95%可信區間(CI).結果 多變量logistic迴歸分析顯示-1195AA和-765GC基因型與肝癌風險增高相關,OR值分彆為1.57(95%CI=1.01~2.44)和2.89(95%CI=1.65~5.08).單體型分析顯示:與A_1290-G-1195-G_765相比較,含有-1195A等位基因的A-1290-A-1195-G-765和A-1290-A-1195-C-765兩種單體型髮生肝癌的相對風險增高,OR值分彆為1.27(95%CI=1.01~1.60)和7.95(95%CI=1.76~36.02).同時包含-1195A等位基因和-765C等位基因的單體型髮生肝癌的OR值較高.結論 COX-2基因啟動子區的-1195G>A和-765G>C單覈苷痠多態與肝癌遺傳易感性相關.
목적 탐토COX-2기인계동자구적단핵감산다태여간암발생풍험적관계.방법 연구대상포괄270례간암병인화540례정상대조.채용PCR-한제성편단장도다태방법 진행COX-2기인계동자구-1290A>G,-1195G>A화-765G>C다태적기인형분석,불동기인형여단체형휴대자발생간암적상대풍험도적평고사용비치비(OR)급95%가신구간(CI).결과 다변량logistic회귀분석현시-1195AA화-765GC기인형여간암풍험증고상관,OR치분별위1.57(95%CI=1.01~2.44)화2.89(95%CI=1.65~5.08).단체형분석현시:여A_1290-G-1195-G_765상비교,함유-1195A등위기인적A-1290-A-1195-G-765화A-1290-A-1195-C-765량충단체형발생간암적상대풍험증고,OR치분별위1.27(95%CI=1.01~1.60)화7.95(95%CI=1.76~36.02).동시포함-1195A등위기인화-765C등위기인적단체형발생간암적OR치교고.결론 COX-2기인계동자구적-1195G>A화-765G>C단핵감산다태여간암유전역감성상관.
Objective To evaluate the effects of SNPs in the promoter of COX-2 gene on the risk of developing hepatocellular carcinoma. Methods Genotypes of 270 cases of hepatocellular carci-noma and 640 control subjects were determined by polymerase chain reaction-based restriction frag-ment length polymorphism (PCR-RFLP). The samples of DNA were extracted from the peripheral blood of all subjects. All patients with hepatocellular carcinoma were diagnosed by pathological or cy-tological examination. Ors and 96% CI were calculated by logistic regression to explore the associa-tion between different genotypes or haplotypes and the risk of hepatocellular carcinoma. Results Three SNPs, -1290A>G, -1195G>A and -765G>C were identified. A case-control analysis re-vealed 1.57-fold (95% CI=1.01-2.44) and 2.89-fold (95% CI=1.65-5.08) excess risks of develo-ping hepatocellular carcinoma for the -1195AA or -765CG genotype carriers compared with noncar-riers, respectively. Compared with A-1290-G-1195-G-765 containing haplotype,greater risks of develo-ping hepatocellular carcinoma were observed for A1290-A-1195-G-765 (OR= 1.27; 95% CI= 1.01 -1.60) and A-1290-A-1195-C-765(OR= 7.95; 95% CI= 1.76-36.02) containing haplotypes. A greater risk of developing hepatoeellular carcinoma was observed for A-1195and C-765 containing haplotype compared with other haplotypes, suggesting an interaction between the -1195A and -765C in the context of haplotype. Conclusion The SNP of -1195A>G and -765G>C in the COX-2 promoter may play an important role in mediating hereditary susceptibility to developing hepatocellular carcinoma.